No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Gland Pharma Limited specializes in the production and global distribution of injectable pharmaceutical formulations, with significant markets spanning India, the United States, Europe, Canada, Australia, and New Zealand. The company actively invests in the research and development of active pharmaceutical ingredients (APIs), focusing on the synthesis of complex drug molecules such as low molecular weight heparins (LMWH), corticosteroids, peptides, and cytotoxic agents. Its extensive product portfolio addresses a wide array of therapeutic areas, including anti-malarial, anti-infective, anti-neoplastic, blood-related, cardiovascular, gastrointestinal, gynecological, hormonal, neurological/CNS, ophthalmological/oncological needs, pain and analgesics, respiratory conditions, and nutritional supplements (vitamins, minerals, and nutrients). Complementing its product offerings, Gland Pharma also provides contract development services. Established in 1978 and headquartered in Hyderabad, India, the company operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
www.glandpharma.comNo one on the platform currently holds GLAND.BO.
No tracked institution reports a position in GLAND.BO as of their last filing.
No one on the platform has traded GLAND.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.6% | 14.8% | 18.7% | — | — | — |
| Rev. Growth % | 14.5% | 13.2% | ||||
| Profit Margin % | 16.0% | 18.2% | 21.9% | |||
| Free Cash Flow Margin % | 11.5% | 8.3% | 10.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $74.5B | +17.1% | $81.32 | $74.22–$90.84 | — | 13 |
| 2028 | $85.2B | +14.3% | $98.78 | $88.10–$109.32 | — | 13 |
| 2029 | $98.0B | +15.0% | $115.21 | $99.81–$133.69 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $18.56 | $19.22 | +3.6% |
| 2026-05-15 | $16.25 | $22.30 | +37.2% |
| 2026-01-27 | $15.37 | $15.87 | +3.3% |
| 2025-11-03 | $13.67 | $11.20 | -18.1% |
| 2025-08-05 | $12.97 | $13.08 | +0.8% |
| 2025-05-20 | $12.51 | $11.30 | -9.7% |
| 2025-02-03 | $12.47 | $12.40 | -0.6% |
| 2024-11-04 | $10.76 | $9.93 | -7.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| GLAND.BOGland Pharma Limited | $2880.45 | -1.69% | $474.9B | — |
| AJANTPHARM.BOAjanta Pharma Limited | $3506.25 | -0.87% | $437.4B | — |
| AJANTPHARM.NSAjanta Pharma Limited | $3510.40 | -0.65% | $438.6B | — |
| IPCALAB.BOIpca Laboratories Limited | $1934.30 | -1.66% | $494.4B | — |
| IPCALAB.NSIpca Laboratories Limited |
| $1938.90 |
| -1.50% |
| $491.9B |
| — |
| JBCHEPHARM.BOJ. B. Chemicals & Pharmaceuticals Limited | $2412.25 | -3.70% | $387.3B | — |
| JBCHEPHARM.NSJ. B. Chemicals & Pharmaceuticals Limited | $2416.10 | +0.30% | $387.9B | — |
Source: Financial Modeling Prep · peers by sector/industry